These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26331899)

  • 1. The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone film.
    White N; Ali R; Larance B; Zador D; Mattick RP; Degenhardt L
    Drug Alcohol Rev; 2016 Jan; 35(1):76-82. PubMed ID: 26331899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia.
    Larance B; Mattick R; Ali R; Lintzeris N; Jenkinson R; White N; Kihas I; Cassidy R; Degenhardt L
    Drug Alcohol Rev; 2016 Jan; 35(1):83-91. PubMed ID: 26450513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
    Larance B; Lintzeris N; Ali R; Dietze P; Mattick R; Jenkinson R; White N; Degenhardt L
    Drug Alcohol Depend; 2014 Mar; 136():21-7. PubMed ID: 24461476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
    Larance B; Degenhardt L; Lintzeris N; Bell J; Winstock A; Dietze P; Mattick R; Ali R; Horyniak D
    Drug Alcohol Depend; 2011 Nov; 118(2-3):265-73. PubMed ID: 21565452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations.
    Larance B; Dietze P; Ali R; Lintzeris N; White N; Jenkinson R; Degenhardt L
    Drug Alcohol Rev; 2015 Nov; 34(6):603-10. PubMed ID: 25950232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia.
    Larney S; Zador D; Sindicich N; Dolan K
    Drug Alcohol Rev; 2017 May; 36(3):305-310. PubMed ID: 27325289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.
    Larance B; Degenhardt L; O'Brien S; Lintzeris N; Winstock A; Mattick RP; Bell J; Ali R
    Drug Alcohol Rev; 2011 Nov; 30(6):613-20. PubMed ID: 21355939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
    Johnson B; Richert T
    Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimising opioid substitution therapy in the prison environment.
    Alam F; Wright N; Roberts P; Dhadley S; Townley J; Webster R
    Int J Prison Health; 2019 Dec; 15(4):293-307. PubMed ID: 31532339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid substitution treatment in pretrial prison detention: a case study from Geneva, Switzerland.
    Favrod-Coune T; Baroudi M; Casillas A; Rieder JP; Gétaz L; Barro J; Gaspoz JM; Broers B; Wolff H
    Swiss Med Wkly; 2013; 143():w13898. PubMed ID: 24186493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence.
    Gisev N; Shanahan M; Weatherburn DJ; Mattick RP; Larney S; Burns L; Degenhardt L
    Addiction; 2015 Dec; 110(12):1975-84. PubMed ID: 26212260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative prices of diverted buprenorphine/naloxone and buprenorphine in a UK prison setting: a cross-sectional survey of drug using prisoners.
    Wright NM; Mohammed Z; Hughes GJ
    Drug Alcohol Depend; 2014 Nov; 144():254-8. PubMed ID: 25305714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.
    Degenhardt L; Larance BK; Bell JR; Winstock AR; Lintzeris N; Ali RL; Scheuer N; Mattick RP
    Med J Aust; 2009 Aug; 191(3):161-5. PubMed ID: 19645647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-prescribed use of opioid substitution medication: Patterns and trends in sub-populations of opioid users in Germany.
    Schulte B; Schmidt CS; Strada L; Götzke C; Hiller P; Fischer B; Reimer J
    Int J Drug Policy; 2016 Mar; 29():57-65. PubMed ID: 26818083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study.
    White N; Flaherty I; Higgs P; Larance B; Nielsen S; Degenhardt L; Ali R; Lintzeris N
    Drug Alcohol Rev; 2015 Nov; 34(6):623-9. PubMed ID: 26179339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diversion of methadone and buprenorphine from opioid substitution treatment: the importance of patients' attitudes and norms.
    Johnson B; Richert T
    J Subst Abuse Treat; 2015 Jul; 54():50-5. PubMed ID: 25744650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The paradox of control: An ethnographic analysis of opiate maintenance treatment in a Norwegian prison.
    Mjåland K
    Int J Drug Policy; 2015 Aug; 26(8):781-9. PubMed ID: 26025481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients.
    Launonen E; Alho H; Kotovirta E; Wallace I; Simojoki K
    Int J Drug Policy; 2015 Sep; 26(9):875-82. PubMed ID: 25934054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective.
    Johnson B; Richert T
    J Psychoactive Drugs; 2014; 46(5):427-35. PubMed ID: 25364995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring prison buprenorphine misuse in the United Kingdom: a qualitative study of former prisoners.
    Tompkins CN; Wright NM; Waterman MG; Sheard L
    Int J Prison Health; 2009; 5(2):71-87. PubMed ID: 25759139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.